Trial Profile
A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs ALRN 6924 (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- 06 Oct 2023 Planned End Date changed from 26 Jul 2023 to 30 Apr 2025.
- 06 Oct 2023 Planned primary completion date changed from 26 Jul 2023 to 30 Apr 2025.
- 19 Apr 2023 Status changed from discontinued to active, no longer recruiting.